Technical Insights into VEGF Protein and Its Applications in Biological Detection
Vascular Endothelial Growth Factor (VEGF) is a pivotal growth factor protein that plays a central role in embryonic development, tissue repair, and disease progression by regulating angiogenesis and vascular permeability. Particularly in tumor biology, cardiovascular diseases, and ophthalmic disorders, the overexpression of VEGF is closely linked to pathological processes, making it a crucial biomarker and therapeutic target.

The VEGF family includes multiple members such as VEGF-A, VEGF-B, VEGF-C, VEGF-D, and Placental Growth Factor (PlGF). Among these, VEGF-A is the most representative subtype, often referred to simply as VEGF. By binding to its receptors (e.g., VEGFR-1 and VEGFR-2), VEGF activates downstream signaling pathways, promoting endothelial cell proliferation, migration, and blood vessel formation. Under normal physiological conditions, VEGF participates in wound healing and the regulation of the female reproductive cycle. However, in pathological states such as cancer, diabetic retinopathy, and rheumatoid arthritis, abnormal VEGF expression drives pathological angiogenesis and exacerbates disease progression. Therefore, accurate detection of VEGF levels is essential for studying disease mechanisms, drug development, and clinical monitoring.
 

Biological Functions and Structural Features of VEGF Protein
VEGF is a secreted glycoprotein with a molecular weight of approximately 45 kDa, composed of two identical subunits linked by disulfide bonds. Its gene is located on human chromosome 6p21.3, encoding a protein that contains multiple domains, such as receptor-binding and heparin-binding domains. VEGF expression is regulated by various factors, including hypoxia, inflammatory cytokines, and oncogene activation. Under hypoxic conditions, Hypoxia-Inducible Factor-1α (HIF-1α) upregulates VEGF transcription, serving as a primary driver of angiogenesis in the tumor microenvironment.
 

The biological functions of VEGF are primarily manifested in angiogenesis and the regulation of vascular permeability. During embryonic development, VEGF guides the construction of vascular networks. In adults, it is mainly involved in tissue repair and compensatory responses in ischemic diseases. For example, in myocardial infarction models, increased local VEGF expression promotes collateral circulation and improves blood perfusion. Overexpression of VEGF is also associated with various diseases. In oncology, VEGF supports tumor growth and metastasis by promoting tumor angiogenesis, which supplies nutrients and oxygen to cancer cells. Anti-VEGF therapies (such as bevacizumab) have been successfully applied in clinical practice, highlighting the importance of targeting VEGF. Furthermore, in ophthalmology, VEGF-mediated vascular leakage is a key pathological mechanism in diabetic retinopathy and age-related macular degeneration.
 

VEGF signaling involves complex hierarchical regulation. Upon binding to VEGFR-2, VEGF activates the PI3K/Akt and MAPK pathways, thereby regulating cell survival and proliferation. Simultaneously, VEGF recruits pericytes and inflammatory cells to refine vascular structures. Notably, VEGF exists in multiple splice variants (e.g., VEGF121, VEGF165, and VEGF189), which differ in bioactivity and tissue distribution. VEGF165 is the most common subtype with potent pro-angiogenic activity, whereas longer variants tend to bind more readily to the extracellular matrix. This diversity adds complexity to VEGF detection, necessitating highly specific detection methods.
 

VEGF Detection Methods and the Advantages of ELISA Technology
Common methods for detecting VEGF protein include immunohistochemistry, Western blot, quantitative real-time PCR (qPCR), and Enzyme-Linked Immunosorbent Assay (ELISA). Each method has its pros and cons: immunohistochemistry is suitable for localization analysis but challenging for quantification; Western blot detects protein expression but is labor-intensive and semi-quantitative; qPCR measures mRNA levels but does not directly reflect protein abundance. In contrast, ELISA technology is the preferred choice for VEGF detection due to its high throughput, accurate quantification, and high degree of standardization.
 

Compared to other techniques, ELISA offers additional advantages such as minimal sample consumption, fast detection (typically completed within 2–4 hours), and ease of automation. For high-throughput screening, ELISA is adaptable to 96-well plates, making it ideal for large-scale studies. Our products further enhance stability and reproducibility, with a coefficient of variation (CV) below 10%, meeting Good Laboratory Practice (GLP) standards.
 

As an innovator in the biotechnology field, our company has developed VEGF ELISA Kits (Product Codes: ELK3130, ELK2479, ELK2478) specifically designed for the precise detection of VEGF-A in human, mouse, or rat samples. Based on a sandwich antibody principle, these kits include pre-coated microplates, standards, detection antibodies, and chromogenic reagents. The operational workflow is straightforward and requires no specialized equipment.
 

In terms of product features, our ELISA kits offer the following core advantages:
1.High Sensitivity: With a lower detection limit as low as 5.9 pg/mL, they accurately measure low-abundance samples.
2.High Specificity: The capture antibody targets conserved epitopes of VEGF-A, showing less than 1% cross-reactivity with other family members such as VEGF-B and VEGF-C.
3.Wide Dynamic Range: The standard curve covers 15.63–1000 pg/mL, making it suitable for samples of varying concentrations.
4.Excellent Stability: Reagents have a shelf life of up to 12 months at -20°C, with minimal lot-to-lot variation, ensuring consistent results.
Additionally, the kits provide optimized sample dilution protocols and support various sample types, including serum, plasma, cell culture supernatants, and tissue homogenates.
 

VEGF protein holds a central position in both physiological and pathological processes, making its accurate detection vital for research and clinical applications. As a mainstream technology, ELISA balances sensitivity, throughput, and cost-effectiveness. Our VEGF ELISA Kits, through optimized design, offer users a reliable and efficient solution.